{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:07:48Z","timestamp":1772816868067,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1245\/s10434-020-09158-2","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T20:13:14Z","timestamp":1601410394000},"page":"3383-3393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-0915","authenticated-orcid":false,"given":"Colin","family":"Bergstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colton","family":"Pence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Partain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navid","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pirzadeh-Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Unni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"3","key":"9158_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA."},{"key":"9158_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J,\u00a0et al.\u00a0Breast cancer.\u00a0Nat Rev Dis Primers. 2019;5:1\u201331.","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"9158_CR3","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A Cancer statistics, 2020. CA: Cancer J Clin. 2020; 70(1): 7\u201330","journal-title":"CA: Cancer J Clin"},{"issue":"4","key":"9158_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","volume":"18","author":"MB Daly","year":"2020","unstructured":"Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017. J Nat Comprehensive Cancer Netw. 2020;18(4):380-391.","journal-title":"J Nat Comprehensive Cancer Netw."},{"issue":"15","key":"9158_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, M\u00f8ller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u20131553.","journal-title":"J Clin Oncol."},{"issue":"9","key":"9158_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967\u2013975.","journal-title":"JAMA."},{"issue":"7","key":"9158_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"1","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment.\u00a0JAMA Oncol.\u00a02015;1(7):943\u2013951.","journal-title":"JAMA Oncol."},{"issue":"25","key":"9158_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","volume":"380","author":"JA Sparano","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25): 2395.","journal-title":"N Engl J Med."},{"issue":"21","key":"9158_CR9","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer.\u00a0N Engl J Med. 2015;373(21):2005\u20132014.","journal-title":"N Engl J Med."},{"issue":"26","key":"9158_CR10","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1056\/NEJM199112263252602","volume":"325","author":"M Swift","year":"1991","unstructured":"Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia.\u00a0N Engl J Med. 1991;325(26):1831-1836.","journal-title":"N Engl J Med."},{"issue":"1","key":"9158_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.\u00a0Nat Genet. 2002;31(1): 55\u201359.","journal-title":"Nat Genet."},{"issue":"6","key":"9158_CR12","doi-asserted-by":"publisher","first-page":"R629","DOI":"10.1186\/bcr933","volume":"6","author":"DM Friedrichsen","year":"2004","unstructured":"Friedrichsen DM, Malone KE, Doody DR, Daling JR, Ostrander EA. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.\u00a0Breast Cancer Res. 2004;6(6):R629\u2013R635.","journal-title":"Breast Cancer Res."},{"issue":"9","key":"9158_CR13","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer.\u00a0JAMA Oncol. 2017;3(9):1190\u20131196.","journal-title":"JAMA Oncol."},{"issue":"14","key":"9158_CR14","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1002\/cncr.32905","volume":"126","author":"J Zhou","year":"2020","unstructured":"Zhou J, Wang H, Fu F, et al. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.\u00a0Cancer. 2020;126(14):3202\u20133208.","journal-title":"Cancer."},{"key":"9158_CR15","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC.\u00a0Gene-panel sequencing and the prediction of breast-cancer risk.\u00a0N Engl J Med. 2015;372:2243\u20132257.","journal-title":"N Engl J Med"},{"key":"9158_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","volume":"16","author":"C Cybulski","year":"2015","unstructured":"Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16:638\u2013644.","journal-title":"Lancet Oncol"},{"issue":"3","key":"9158_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.radonc.2006.12.002","volume":"82","author":"A Meyer","year":"2007","unstructured":"Meyer A, D\u00f6rk T, Sohn C, Karstens JH, Bremer M. Breast cancer in patients carrying a germ-line CHEK2 mutation: outcome after breast conserving surgery and adjuvant radiotherapy.\u00a0Radiother Oncol. 2007;82(3):349\u2013353.","journal-title":"Radiother Oncol."},{"issue":"11","key":"9158_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00432-010-0824-9","volume":"136","author":"SS Bozhanov","year":"2010","unstructured":"Bozhanov SS, Angelova SG, Krasteva ME, et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.\u00a0J Cancer Res Clin Oncol. 2010;136(11):1657\u20131669.","journal-title":"J Cancer Res Clin Oncol."},{"key":"9158_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/cpr.13.72","volume":"10","author":"JO Murphy","year":"2013","unstructured":"Murphy JO, Sacchini VS. Breast cancer in BRCA mutation carriers: breast-conserving therapy or bilateral mastectomy? Clin Pract. 2013;10:751\u2013764","journal-title":"Clin Pract."},{"issue":"3","key":"9158_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/SLA.0b013e3181c3c36d","volume":"251","author":"R Kaas","year":"2010","unstructured":"Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.\u00a0Ann Surg. 2010;251(3):488\u2013492.","journal-title":"Ann Surg."},{"issue":"16","key":"9158_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa020989","volume":"347","author":"U Veronesi","year":"2002","unstructured":"Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.\u00a0N Engl J Med. 2002;347(16):1227\u20131232.","journal-title":"N Engl J Med."},{"issue":"4","key":"9158_CR22","doi-asserted-by":"publisher","first-page":"e196400","DOI":"10.1001\/jamaoncol.2019.6400","volume":"6","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Ward KC, Abrahamse P, et al. Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer.\u00a0JAMA Oncol.\u00a02020;6(4): e196400.","journal-title":"JAMA Oncol."},{"key":"9158_CR23","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","volume":"34","author":"C Naslund-Koch","year":"2016","unstructured":"Naslund-Koch\u00a0C,\u00a0Nordestgaard\u00a0BG,\u00a0Bojesen\u00a0SE.\u00a0Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the copenhagen general population study.\u00a0J Clin Oncol.\u00a02016;34:1208\u20131216.","journal-title":"J Clin Oncol."},{"key":"9158_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1086\/421251","volume":"74","author":"The CHEK2 Breast Cancer Case-Control Consortium","year":"2004","unstructured":"The CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from ten studies. Am J Hum Genet. 2004;74: 1175\u20131182","journal-title":"Am J Hum Genet."},{"key":"9158_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou\u00a0AC,\u00a0Casadei\u00a0S,\u00a0Heikkinen\u00a0T.\u00a0Breast-cancer risk in families with mutations in PALB2.\u00a0N Engl J Med. 2014;371:497\u2013506.","journal-title":"N Engl J Med"},{"issue":"11","key":"9158_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.neo.2014.09.009","volume":"16","author":"TM Abdel-Fatah","year":"2014","unstructured":"Abdel-Fatah TM, Arora A, Alsubhi N, et al. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.\u00a0Neoplasia. 2014;16(11):982\u2013991.","journal-title":"Neoplasia."},{"issue":"9","key":"9158_CR27","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","volume":"15","author":"T Heikkinen","year":"2009","unstructured":"Heikkinen T, K\u00e4rkk\u00e4inen H, Aaltonen K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.\u00a0Clin Cancer Res. 2009;15(9):3214\u20133222.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"9158_CR28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/bjc.2014.306","volume":"111","author":"M Kriege","year":"2014","unstructured":"Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.\u00a0Br J Cancer. 2014;111(5):1004\u20131013.","journal-title":"Br J Cancer."},{"issue":"1","key":"9158_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","volume":"25","author":"MK Schmidt","year":"2007","unstructured":"Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.\u00a0J Clin Oncol. 2007;25(1):64\u201369.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09158-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:13:33Z","timestamp":1632870813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09158-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9158"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09158-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"20 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Colin Bergstrom, Colton Pence, Jordan Berg, Natalia Partain, Navid Sadeghi, Caitlin Mauer, Sara Pirzadeh-Miller, Ang Gao, Hsiao Li, Nisha Unni, and Samira Syed report no disclosures or conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}